Effect of <scp>UGT1A1</scp>, <scp>UGT1A3</scp>, <scp>DIO1</scp> and <scp>DIO2</scp> polymorphisms on <scp>L</scp>‐thyroxine doses required for <scp>TSH</scp> suppression in patients with differentiated thyroid cancer - Concepedia

Concepedia

Publication | Open Access

Effect of <scp>UGT1A1</scp>, <scp>UGT1A3</scp>, <scp>DIO1</scp> and <scp>DIO2</scp> polymorphisms on <scp>L</scp>‐thyroxine doses required for <scp>TSH</scp> suppression in patients with differentiated thyroid cancer

DOI Full Paper Access

32

Citations

29

References

2014

Year

Ana Santoro, Daniela D. Vargens, Mateus Camargo Barros‐Filho, Daniel Bulzico, Luiz Paulo Kowalski, Ricardo M.R. Meirelles, Daniela Polessa Paula, Ronaldo R. S. Neves, Cencita N. Pessoa, Claudio J. Struchine,

British Journal of Clinical Pharmacology

Abstract

UGT1A haplotypes associate with T4 dosage in DTC patients, but the effect accounts for only 2% of the total variability and recommendation of pre-emptive UGT1A genotyping is not warranted.

References

	Year	Citations

Page 1